Charles K. Dargan - 22 Mar 2022 Form 4 Insider Report for BIOLARGO, INC. (BLGO)

Role
Chief Financial Officer
Signature
/s/ John R. Browning, Attorney-in-fact
Issuer symbol
BLGO
Transactions as of
22 Mar 2022
Net transactions value
$0
Form type
4
Filing time
28 Mar 2022, 21:27:07 UTC
Previous filing
24 May 2021
Next filing
04 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLGO Option to purchase common stock Award +300,000 +8.2% 3,959,000 22 Mar 2022 Common stock 300,000 $0.2400 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Option is exercisable according to its vesting schedule: (i) 25,000 shares vested as of March 22, 2022, and then (ii) in equal monthly installments of 25,000 shares beginning March 31, 2022, so long as the Engagement Extension Agreement dated March 20, 2022, between Reporting Owner and Issuer, remains in force and effect.
F2 This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from February 1, 2022, through January 31, 2023.

Remarks:

This transaction was disclosed by the Issuer on Form 8-K filed with the SEC on March 24, 2022.